Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Background: The overlapping epidemics of opioid use disorder (OUD) and HIV present a critical public health challenge. Although people with OUD frequently engage with healthcare settings, uptake of HIV prevention services such as pre-exposure prophylaxis (PrEP) remains low. Integrating HIV prevention into routine OUD care could reduce new infections, but scalable, evidence-based strategies are lacking. Rhode Island offers a unique opportunity to design and evaluate such strategies using its robust data infrastructure and high OUD burden.

Methods: We will conduct a three-phase, sequential implementation study. In Aim 1, we will use the Rhode Island All-Payer Claims Database and State Emergency Department Database data to identify healthcare engagement patterns and gaps in HIV prevention service delivery among people with OUD, including rates of HIV screening, PrEP use, and medications for OUD uptake, across settings from 2012 to 2022. In Aim 2, we will convene a series of five stakeholder-engaged evidence-based quality improvement panels-including with providers, policymakers, and people with lived experience-to co-develop implementation strategies tailored to each care setting (i.e., primary care, mental health clinics, emergency department, and opioid use treatment centers). Finally, in Aim 3, we will develop an agent-based model (ABM) to simulate the population-level effect of implementation strategies developed for each care setting (as identified in Aim 2). The ABM will project outcomes such as HIV incidence, cases averted, and number needed to treat (NNT) over 5- and 10-year horizons under various scenarios. Model parameters will be based on literature and findings from Aim 1. Outputs from the ABM will be used to prioritize feasible, high-impact strategies for future real-world implementation.

Discussion: This study addresses critical gaps in HIV prevention for people with OUD by combining claims-based analysis, evidence-based quality improvement, and agent-based modeling. By leveraging real-world data and engaging diverse stakeholders, the study aims to generate actionable strategies tailored to clinical settings. Findings will inform future implementation efforts in Rhode Island and other jurisdictions facing overlapping HIV and opioid epidemics.

Trial Registration: This study does not meet the World Health Organization's definition of a clinical trial and, therefore, was not registered.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12400686PMC
http://dx.doi.org/10.1186/s43058-025-00782-1DOI Listing

Publication Analysis

Top Keywords

hiv prevention
20
people oud
12
rhode island
12
aim will
12
integrating hiv
8
prevention services
8
opioid disorder
8
oud
8
disorder oud
8
hiv
8

Similar Publications

In the U.S., HIV diagnoses have remained steady over the past decade - despite the availability of condoms and pre-exposure prophylaxis.

View Article and Find Full Text PDF

Human immunodeficiency viruses (HIV) and, subsequently, acquired immune deficiency syndrome emphasize the significance of prevention and treatment, especially among vulnerable populations. Some subgroups of the LGBTQIA+ community, namely men who have sex with men (MSM) and transgender individuals, can be disproportionately affected by this disease. As the health care community recognizes this health concern, post-exposure prophylaxis has become important in preventing HIV spread.

View Article and Find Full Text PDF

HIV-1-mediated CD4 downregulation is a well-known mechanism that protects infected cells from antibody-dependent cellular cytotoxicity (ADCC). While CD4 downregulation by HIV-1 Nef and Vpu proteins has been extensively studied, the contribution of the HIV-1 envelope glycoprotein (Env) in this mechanism is less understood. While Env is known to retain CD4 in the endoplasmic reticulum (ER) through its CD4-binding site (CD4bs), little is known about the mechanisms underlying this process.

View Article and Find Full Text PDF

HIV-induced gut microbiota dysbiosis perpetuates mucosal barrier disruption and systemic inflammation despite antiretroviral therapy (ART), creating a tumor-permissive microenvironment. This review synthesizes evidence linking HIV-associated microbial alterations to oncogenesis through three convergent metabolic axes: (1) butyrate deficiency impairing epithelial energy metabolism and anti-tumor immunity; (2) tryptophan metabolism dysregulation compromising gut barrier integrity via depletion and -mediated phenylethylamine overproduction; and (3) vitamin B biosynthesis defects disrupting DNA repair and Th1/Th2 balance. Comparative profiling across HIV-associated malignancies-non-Hodgkin lymphoma, cervical cancer, hepatocellular carcinoma, and lung cancer-reveals conserved dysbiotic signatures: depletion of anti-inflammatory taxa (, ) and expansion of pro-inflammatory genera (, ).

View Article and Find Full Text PDF

Introduction: HIV-negative adolescent girls and young women (AGYW), and men (ABYM), have disproportionately high HIV incidence in many African countries. We used a new HIV Prevention Cascade (HPC) approach to quantify levels of, and barriers to, prevention method use to guide interventions to increase effective uptake of primary HIV prevention.

Methods: Data from the Manicaland HPC pilot study (2018-19; n=9803) in Zimbabwe were used to measure levels of sexual risk behaviour and construct HPCs for male condom, pre-exposure prophylaxis (females), voluntary medical male circumcision (males) and combination prevention use by HIV-negative sexually active AGYW (15-24 years) and male partners (15-29 years).

View Article and Find Full Text PDF